Management of Apixaban in Gross Hematuria

Immediate Management

The American College of Cardiology recommends stopping apixaban immediately when gross hematuria is present, as this meets the criteria for major bleeding requiring anticoagulation cessation, defined as clinically overt bleeding with hemoglobin decrease ≥2 g/dL or requiring ≥2 units of red blood cells, or bleeding at a critical site 1
Provide local therapy and supportive care, including volume resuscitation as needed, to patients with gross hematuria on apixaban 1
Assess for comorbidities that could contribute to bleeding, such as thrombocytopenia, uremia, or liver disease, in patients on apixaban with gross hematuria 1
Consider urologic consultation for cystoscopy or other procedures to identify and manage the bleeding source in patients with gross hematuria on apixaban 1
Stop any concurrent antiplatelet agents, such as aspirin or other antiplatelet medications, as combination therapy significantly increases bleeding risk in patients on apixaban 2

Do not routinely administer reversal agents, such as andexanet alfa, for non-life-threatening gross hematuria in patients on apixaban, but reserve them for life-threatening bleeding, bleeding at critical sites, or hemodynamically unstable patients 1
Apixaban has a half-life of approximately 12 hours in patients with normal renal function, and the drug effect will diminish over 24-48 hours after the last dose 3
If the patient has renal impairment, the half-life of apixaban is prolonged to 17 hours, requiring longer observation 3

Renal impairment, advanced age, concurrent antiplatelet use, and low body weight (<60 kg) increase bleeding risk with apixaban 2

Do not restart apixaban until the bleeding source has been identified and controlled, the patient is hemodynamically stable, adequate time has passed for drug elimination (typically 24-48 hours), and the underlying indication for anticoagulation has been reassessed 1
Delay restarting apixaban if the source of bleeding has not been identified, surgical or invasive urologic procedures are planned, or the patient is at high risk of rebleeding 1

Monitor hemoglobin/hematocrit serially to assess for ongoing blood loss in patients who have had apixaban held due to gross hematuria 1